Search
Menu
Home
Sources
About
Contacts
Simtuzumab
Simtuzumab
is a
humanized monoclonal antibody
designed for the
treatment
of
fibrosis
. It
binds
to
LOXL2
and
acts
as an
immunomodulator
. In
January 2016
,
Gilead Sciences
terminated
its
Phase 2
clinical study
in
patients
with
idiopathic pulmonary fibrosis
due to
lack
of
efficacy
.